Akums Drugs & Pharma
Ticker > Company >

Akums Drugs & Pharma share price

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS BSE: 544222 SECTOR: Pharmaceuticals & Drugs  24k   24   12

452.80
+4.20 (0.94%)
BSE: 04 Apr 04:01 PM

Price Summary

Today's High

₹ 485

Today's Low

₹ 440

52 Week High

₹ 1174.85

52 Week Low

₹ 433.75

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 7126.8 Cr.

Enterprise Value

₹ 7126.8 Cr.

No. of Shares

15.74 Cr.

P/E

0

P/B

2.46

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  184.29

CASH

0

DEBT

₹ 0 Cr.

Promoter Holding

75.26 %

EPS (TTM)

₹  -0.26

Sales Growth

ROE

ROCE

Profit Growth

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.32%
3 Year15.35%
5 Year15.78%

Profit Growth

1 Year-99.19%
3 Year-81.42%
5 Year-58.98%

ROE%

1 Year0.11%
3 Year-6.19%
5 Year0.45%

ROCE %

1 Year0.43%
3 Year0.01%
5 Year6.46%

Debt/Equity

0.6928

Price to Cash Flow

∞

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 75.26 0.00
Sep 2024 75.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 15.3450626411259% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • Company has a poor ROE of -6.193% over the past 3 years.
  • Company has a poor ROCE of 0.0106666666666667% over the past 3 years
  • Company has low Interest coverage ratio of 0.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 42.831.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024
Net Sales 1019.11 1033.09 1010.41
Total Expenditure 891.1 911.9 889.05
Operating Profit 128.02 121.19 121.37
Other Income 6.55 13.47 14.56
Interest 13.02 11.9 5.13
Depreciation 34.06 34.87 44.52
Exceptional Items 0 3.7 4.78
Profit Before Tax 87.48 91.59 91.05
Tax 26.27 24.94 24.74
Profit After Tax 61.21 66.65 66.31
Adjustments -1.04 -1.45 -1.13
Consolidated Net Profit 60.17 65.21 65.18
Adjusted EPS (Rs) 4.21 4.26 4.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2414.16 2722.63 3671.89 3654.82 4178.18
Total Expenditure 2240.05 2431.46 3763.61 3360.84 4055.2
Operating Profit 174.11 291.17 -91.72 293.98 122.99
Other Income 27.49 21.16 22.63 90.07 34.03
Interest 19.93 6.74 16.66 46.25 50.61
Depreciation 66.68 69.84 94.68 112.81 125.64
Exceptional Items -1.16 -63.82 -12.98 -74.5 -26.03
Profit Before Tax 113.82 171.91 -193.2 150.3 -45.28
Tax 70.17 48.83 57.68 52.48 -46.07
Profit After Tax 43.65 123.09 -250.87 97.82 0.79
Adjustments 4.13 -0.38 -1.66 -2.96 -4.83
Consolidated Net Profit 47.78 122.71 -252.54 94.86 -4.04
Adjusted EPS (Rs.) 3.34 8.57 -17.65 6.63 -0.28

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 1.3 1.3 14.31 28.61 28.61
Total Reserves 721.1 883.55 607.67 688.58 680.89
Minority Interest -1.51 2.29 3.2 6.19 10.99
Borrowings 9.85 1.16 13.33 115.5 78.3
Other N/C liabilities 576.08 683.92 1139.27 1130.57 1383.97
Current liabilities 729.98 579.95 1272.42 1265.57 1210.55
Total Liabilities 2036.8 2152.17 3050.2 3235.01 3393.3
Assets
Net Block 644.38 903.99 1020.54 1097.31 1190.77
Capital WIP 56.6 17.01 30.82 102.99 195.13
Intangible WIP 0 0 0.25 0.16 0.28
Investments 0.56 0.53 0.39 0.14 0.14
Loans & Advances 35.78 43.76 86.1 96.39 56.36
Other N/C Assets 49.64 29.48 48.04 59.14 9.84
Current Assets 1249.85 1157.41 1864.06 1878.87 1940.78
Total Assets 2036.8 2152.17 3050.2 3235.01 3393.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 113.82 172.26 -193.2 150.3 -45.28
Adjustment 77.91 144.02 631.42 157.73 556.09
Changes in Assets & Liabilities -114.87 -136.84 -351.56 -34.33 49.87
Tax Paid -48.73 -45.55 -54.82 -97.06 -62.42
Operating Cash Flow 28.13 133.89 31.85 176.63 498.26
Investing Cash Flow -189.87 -108.87 -234.82 -304.7 -330.8
Financing Cash Flow 233.01 -94.74 236.04 124.54 -108.02
Net Cash Flow 71.28 -69.72 33.07 -3.53 59.44

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024%
promoters 75.26 75.26
akums master trust (sanje... - 40.79
lata jain 0.01 0.01
sandeep jain 17.24 17.24
sanjeev jain 17.23 17.23
akums master trust 40.79 -
PARTICULARS Sep 2024% Dec 2024%
investors 24.74 24.74
akums employee benefits t... 2.73 2.73
franklin india smaller co... 1.71 2.12
llp 0.01 0.02
ruby qc investment holdin... 4.62 4.62
smallcap world fund, inc 2.15 2.15

Annual Reports

No Annual reports exist for this company.Report us

Ratings & Research Reports

Company Presentations

Company News

Akums Drugs and Pharmaceuticals informs about resignation of senior management personnel 26 Mar, 3:45 PM Akums Drugs secures patent for 'Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation' 15 Feb, 5:00 PM Akums Drugs and Pharmaceuticals informs about newspaper publication 15 Feb, 4:06 PM Akums Drugs and Pharmaceuticals reports 66% drop in Q3 consolidated net profit 7 Feb, 4:27 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs and Pharmaceuticals informs about analyst meet 3 Feb, 2:58 PM Akums Drugs and Pharmaceuticals informs about disclosure 22 Jan, 12:31 PM Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations 24 Dec, 3:28 PM Akums Drugs and Pharmaceuticals informs about updates 26 Nov, 5:11 PM Akums Drugs’ arm collaborates with Jagdale Industries 26 Nov, 3:42 PM Akums Drugs enters into exclusive Master Sales Agreement with Caregen 19 Nov, 2:51 PM Akums Drugs and Pharmaceuticals informs about press release 11 Nov, 2:38 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs and Pharmaceuticals enters into MoU with Government of Republic of Zambia 18 Oct, 2:27 PM Akums Drugs & Pharmaceuticals enters into license & distribution agreement with Triple Hair Inc 16 Oct, 3:45 PM Akums Drugs launches new product Famotidine, Calcium Carbonate and Magnesium Hydroxide 10 Oct, 9:22 AM Akums Drugs and Pharmaceuticals informs about closure of trading window 30 Sep, 12:33 PM Akums Drugs gets patent certificate from Government of India 13 Sep, 10:46 AM Akums Drugs and Pharmaceuticals informs about newspaper publication 26 Aug, 12:41 PM Akums Drugs & Pharmaceuticals - Quaterly Results 24 Aug, 5:30 PM Akums Drugs and Pharmaceuticals informs about earnings call 23 Aug, 2:49 PM Akums Drugs’ arm starts second production facility at Haridwar manufacturing unit 23 Aug, 11:00 AM Akums Drugs and Pharmaceuticals coming with IPO to raise upto Rs 1893.21 crore 27 Jul, 12:58 PM Akums Drugs and Pharmaceuticals gets SEBI’s nod for IPO 9 Jul, 2:40 PM Akums Drugs and Pharmaceuticals files DRHP with SEBI 14 Feb, 12:38 PM
Last Updated on:
Brief about Akums Drugs & Pharma
X